Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18907606 | ANTIBACTERIAL MODIFIED CHITOSAN-BASED HEMOSTATIC MATERIAL AND METHOD OF MANUFACTURING THE SAME | October 2024 | January 2025 | Allow | 3 | 0 | 1 | No | No |
| 18818636 | CHITOSAN COMPOSITION AND METHOD OF MANUFACTURING THE SAME | August 2024 | November 2024 | Allow | 2 | 0 | 0 | No | No |
| 18796479 | Curcuminoid composition of Curcumin-keto, method of preparation and use thereof | August 2024 | November 2024 | Allow | 3 | 1 | 0 | Yes | No |
| 18630703 | COMPOSITION FOR IMPROVING SKIN MOISTURIZATION OF COMPANION ANIMALS | April 2024 | July 2024 | Allow | 4 | 1 | 0 | No | No |
| 18594014 | PROCESS OF MANUFACTURING COMPOSITION FOR THE PREVENTION AND TREATMENT OF EARLY MORTALITY SYNDROME (EMS) SHRIMP | March 2024 | July 2024 | Allow | 4 | 1 | 1 | No | No |
| 18592551 | METHOD FOR PRODUCING A COMPLEX COMPOSITION OF TURKEY TAIL MUSHROOM EXTRACT- CHITOSAN | March 2024 | June 2024 | Allow | 3 | 1 | 1 | No | No |
| 18683505 | LIQUID-LIQUID EXTRACTION OF PURIFIED PSYCHOACTIVE ALKALOID | February 2024 | September 2024 | Allow | 7 | 1 | 0 | No | No |
| 18424092 | A METHOD OF PREVENTING CADMIUM-INDUCED RENAL TOXICITY USING A PLANT PRODUCT DERIVED FROM ACHILLEA MILLEFOLIUM L. | January 2024 | July 2024 | Allow | 6 | 1 | 0 | No | No |
| 18406509 | METHOD FOR PRODUCING THERAPEUTIC AGENT FOR SKIN LESIONS, AND THERAPEUTIC AGENT FOR SKIN LESIONS | January 2024 | March 2025 | Allow | 15 | 1 | 0 | No | No |
| 18395180 | SEPARATION AND IDENTIFICATION OF MYRICETIN-3-OGALACTOSIDE FROM CASUARINA GLAUCA | December 2023 | October 2024 | Allow | 10 | 1 | 1 | No | No |
| 18391502 | XENOGRAFT SOFT TISSUE IMPLANTS AND METHODS OF MAKING | December 2023 | March 2025 | Allow | 15 | 1 | 0 | No | No |
| 18383606 | Compositions and Methods of Achieving Pain Relief | October 2023 | March 2025 | Allow | 17 | 1 | 0 | Yes | No |
| 18381542 | MIXTURE OF CYANOBACTERIA, CHITOSAN, AND PLANT EXTRACTS FOR WOUND HEALING AND ELIMINATING PATHOGEN BACTERIA | October 2023 | August 2024 | Allow | 10 | 2 | 0 | No | No |
| 18381479 | MIXTURE OF CYANOBACTERIA, CHITOSAN, AND PLANT EXTRACTS FOR WOUND HEALING AND ELIMINATING PATHOGEN BACTERIA | October 2023 | May 2025 | Abandon | 19 | 4 | 0 | Yes | No |
| 18554058 | Acoustically Responsive Biomaterials | October 2023 | April 2025 | Allow | 19 | 1 | 2 | No | No |
| 18475217 | COMPOSITIONS CONTAINING HONEY AND LANOLIN | September 2023 | February 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18228865 | FECAL MICROBIOTA TRANSPLANT COMPOSITIONS AND METHODS OF MANUFACTURE | August 2023 | March 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18227930 | RAPID INDUCTION OF CELL-MEDIATED IMMUNITY | July 2023 | April 2024 | Allow | 9 | 2 | 1 | Yes | No |
| 18220155 | MIXTURE OF CYANOBACTERIA, CHITOSAN, AND PLANT EXTRACTS FOR WOUND HEALING AND ELIMINATING PATHOGEN BACTERIA | July 2023 | January 2025 | Abandon | 19 | 3 | 1 | No | No |
| 18334565 | CANNABIDIOL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION | June 2023 | June 2025 | Allow | 24 | 1 | 1 | No | No |
| 18208490 | LUTEINIZING HORMONE RECEPTOR BINDING AGENTS AND LUTEINIZING HORMONE AGONISTS TO IDENTIFY, EXPAND, ABLATE AND MODIFY STEM CELLS | June 2023 | January 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18332063 | METHOD FOR ISOLATION AND PURIFICATION OF MICROVESICLES FROM CELL CULTURE SUPERNATANTS AND BIOLOGICAL FLUIDS | June 2023 | June 2025 | Allow | 25 | 2 | 1 | No | No |
| 18299797 | SYSTEMS AND METHODS FOR PRODUCING HEMP EXTRACTS AND COMPOSITIONS | April 2023 | August 2024 | Allow | 16 | 0 | 0 | No | No |
| 18133791 | Method Of Treatment Or Alleviating Symptoms Of A Disorder With Cannabidiol | April 2023 | April 2024 | Allow | 12 | 0 | 0 | No | No |
| 18298023 | COMPOUNDS FOR USE IN REGULATING FOLLICLE MATURATION | April 2023 | September 2024 | Allow | 18 | 0 | 1 | No | No |
| 18127542 | CREATINE NUTRITIONAL SUPPLEMENT | March 2023 | November 2023 | Allow | 7 | 3 | 0 | Yes | No |
| 18185409 | METHOD FOR SCAVENGING FREE RADICALS IN CELL USING CHENOPODIUM FORMOSANUM (DJULIS) EXTRACT | March 2023 | September 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18115929 | TOPICAL CREAM-BASED COSMETIC AND WOUND HEALING FORMULATIONS AND METHODS OF USE | March 2023 | June 2025 | Allow | 27 | 2 | 1 | Yes | No |
| 18115927 | AQUEOUS EXTRACTION PROCESS OF PLANTS, METHOD THEREOF, AND PRODUCT BY PROCESS | March 2023 | February 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18168249 | CANNABIS EXTRACTION SYSTEM AND METHOD | February 2023 | June 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18150364 | COMPOSITIONS AND METHODS FOR TREATMENT OF ADDICTION WITHDRAWAL SYMPTOMS | January 2023 | July 2023 | Allow | 6 | 1 | 1 | Yes | No |
| 18080952 | COMPOSITION CONTAINING PERILLA FRUTESCENS FERMENTED EXTRACT FOR PREVENTION, ALLEVIATION, OR TREATMENT OF SLEEP DISORDER | December 2022 | November 2024 | Abandon | 23 | 1 | 0 | No | No |
| 18063694 | METHOD FOR SKIN BRIGHTENING USING CHENOPODIUM FORMOSANUM (DJULIS) EXTRACT | December 2022 | June 2024 | Allow | 18 | 1 | 0 | No | No |
| 17977541 | METHOD FOR TREATING OR ALLEVIATING AUTOIMMUNE-RELATED DISEASES | October 2022 | March 2025 | Allow | 29 | 2 | 1 | No | No |
| 18049977 | SYSTEMS AND METHODS FOR PRODUCING HEMP EXTRACTS AND COMPOSITIONS | October 2022 | February 2023 | Allow | 4 | 1 | 1 | No | No |
| 18048980 | METHOD FOR IMPROVING EYE CONDITIONS | October 2022 | May 2023 | Allow | 6 | 2 | 1 | Yes | No |
| 17950733 | METHODS AND COMPOSITIONS FOR INHIBITING FUNGAL GROWTH IN FOOD AND COSMETIC PRODUCTS | September 2022 | August 2023 | Allow | 11 | 2 | 1 | No | No |
| 17933224 | APPROACH TO SUSTAINED PRODUCTION AND DELIVERY OF NITRIC OXIDE AND S-NITROSOTHIOLS | September 2022 | August 2023 | Allow | 11 | 1 | 1 | Yes | No |
| 17903284 | METHOD OF ENHANCING COGNITION IN INDIVIDUALS WITH AT LEAST NORMAL COGNITION | September 2022 | November 2023 | Allow | 14 | 2 | 1 | No | Yes |
| 17799784 | MILD CLEANSING COMPOSITION CONTAINING NEARLY SATURATED, SATURATED OR SUPERSATURATED ACTIVE INGREDIENTS AND PREPARATION METHOD THEREFOR | August 2022 | January 2025 | Allow | 30 | 0 | 0 | No | No |
| 17885854 | FUNCTIONAL FOOD COMPOSITION FOR ENHANCING MUSCULAR FUNCTION AND MOBILITY COMPRISING LOTUS LEAF EXTRACT, AND METHOD FOR PREPARING SAME | August 2022 | September 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17810600 | MUSHROOM-CONTAINING CHINESE MEDICINE COMPOUND COMPOSITION FOR KELOID SCAR TISSUE AND APPLICATION THEREOF | July 2022 | May 2024 | Abandon | 22 | 1 | 1 | No | No |
| 17788797 | SYSTEM FOR INTEGRATION INTO A FRUIT PROCESSING FACILITY | June 2022 | April 2024 | Abandon | 22 | 2 | 2 | No | No |
| 17838001 | XENOGRAFT SOFT TISSUE IMPLANTS AND METHODS OF MAKING | June 2022 | September 2023 | Allow | 16 | 0 | 0 | No | No |
| 17831063 | USE OF RAMIE EXTRACT IN PREPARING A COMPOSITION FOR IMPROVING THE ACTIVITY OF MITOCHONDRIA AND IMPROVING THE ACTIVITY OF TELOMERASE | June 2022 | February 2024 | Allow | 20 | 1 | 1 | No | No |
| 17828230 | MACA EXTRACT AND USE THEREOF | May 2022 | June 2023 | Allow | 13 | 0 | 0 | No | No |
| 17748028 | COMPOSITION AND METHOD FOR TREATMENT OF DRY EYE SYNDROME | May 2022 | July 2023 | Allow | 14 | 1 | 1 | No | No |
| 17733370 | METHODS AND COMPOSITIONS FOR TREATING STRIAE DISTENSAE | April 2022 | October 2023 | Allow | 18 | 1 | 0 | No | No |
| 17731636 | CANNABIS COMPOSITIONS AND RELATED METHODS | April 2022 | January 2024 | Abandon | 21 | 0 | 1 | No | No |
| 17660848 | METHODS FOR MAKING BOTANICAL EXTRACT COMPOSITION | April 2022 | January 2024 | Allow | 21 | 1 | 1 | No | No |
| 17728564 | COMPOSITION AND METHOD FOR TREATING DYSPEPSIA | April 2022 | January 2024 | Allow | 21 | 1 | 0 | No | No |
| 17711247 | COMPOSITIONS AND METHODS FOR TREATING SPINAL CORD INJURY AND SYNAPTIC DYSFUNCTION | April 2022 | March 2024 | Abandon | 24 | 3 | 1 | No | Yes |
| 17694116 | ORAL COMPOSITIONS AND METHODS FOR ANIMALS | March 2022 | January 2024 | Allow | 22 | 2 | 0 | No | No |
| 17641821 | Hydrolysate of water soluble insect proteins and method for preparation thereof | March 2022 | February 2025 | Allow | 35 | 0 | 1 | No | No |
| 17638269 | Xenogen-Free Mesenchymal Stem Cell Compositions and Methods of Use | February 2022 | May 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17677158 | OILS WITH ANTI-INFLAMMATORY ACTIVITY CONTAINING NATURAL SPECIALIZED PRORESOLVING MEDIATORS AND THEIR PRECURSORS | February 2022 | September 2023 | Allow | 19 | 0 | 1 | No | No |
| 17676339 | Compositions and Methods of Achieving Pain Relief | February 2022 | March 2024 | Abandon | 25 | 2 | 1 | No | No |
| 17635248 | SENSITIZATION CREAM COMPRISING L-ARGININE AND L-CITRULLINE AND THERAPEUTIC USES THEREOF | February 2022 | October 2024 | Allow | 32 | 0 | 0 | No | No |
| 17666294 | System, Method and Apparatus for Cannabinoid Tincture Separation and Solvent Recovery | February 2022 | November 2022 | Abandon | 10 | 1 | 0 | No | No |
| 17631861 | CROTON LECHLERI COMPOSITIONS FOR USE IN TREATING BLEEDING, WOUNDS AND INFECTIONS | January 2022 | May 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17587789 | TREATMENT OF SEBACEOUS GLAND DISORDERS | January 2022 | April 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17587731 | ETHANOL EXTRACTION OF PSYCHOACTIVE COMPOUNDS FROM PSILOCYBIN FUNGUS | January 2022 | September 2022 | Allow | 8 | 2 | 0 | Yes | No |
| 17586811 | Method for enhancing skin moisture with white roselle extract | January 2022 | September 2023 | Allow | 19 | 1 | 0 | No | No |
| 17630988 | FOOD SUPPLEMENT, FOR AS ADJUVANT, FOR PREVENTING VASCULAR DEMENTIA | January 2022 | January 2025 | Allow | 36 | 1 | 0 | No | No |
| 17578505 | ANTI-OBESITY FUNCTIONAL FEED COMPOSITION CONTAINING HIBISCUS MANIHOT L. EXTRACT AS ACTIVE INGREDIENT FOR COMPANION ANIMALS | January 2022 | January 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17570611 | NOVEL EXOSOME PRODUCTION METHOD AND APPLICATION THEREOF | January 2022 | April 2025 | Abandon | 40 | 1 | 1 | No | No |
| 17563350 | OKRA AS A SUBSTITUTE FOR CERVICAL MUCUS | December 2021 | January 2024 | Allow | 25 | 1 | 1 | No | No |
| 17557019 | COMPOSITIONS AND METHODS FOR PROVIDING SUSTAINED NATURAL SLEEP | December 2021 | March 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17618241 | METHOD FOR SEPARATING PANCREATIC PROGENITOR CELLS | December 2021 | March 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17538711 | CRYOGENIC HOP LUPULIN OR CANNABIS TRICHOME PELLETS | November 2021 | July 2024 | Allow | 31 | 2 | 1 | No | No |
| 17456430 | METHODS FOR ENHANCEMENT OF DEHYDROEPIANDROSTERONE USING GREEN COFFEE BEAN EXTRACT | November 2021 | September 2024 | Abandon | 34 | 4 | 0 | No | No |
| 17613682 | HIGH-ENERGY FOOD SUPPLEMENT BASED ON INVERTED SUGARS AND ERGOGENIC PRODUCTS FOR USE IN PHYSICAL ACTIVITY AND METHOD FOR PRODUCING SAME | November 2021 | February 2025 | Allow | 39 | 1 | 1 | No | No |
| 17613391 | INHIBITORY INTERNEURON TREATMENT METHODS, USES AND COMPOSITIONS FOR DIABETES | November 2021 | March 2025 | Allow | 39 | 0 | 1 | No | No |
| 17528377 | ELASTOMERIC ARTICLES HAVING SKIN CARE PROPERTIES AND METHODS FOR THEIR PRODUCTION | November 2021 | September 2023 | Allow | 22 | 1 | 0 | No | No |
| 17611880 | COMPOSITION FOR USE IN A METHOD FOR PREVENTION OR TREATMENT OF MALTNUTRITION IN A SUBJECT SUFFERING FROM A CHRONIC INFLAMMATORY BOWEL DISEASES | November 2021 | February 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17611080 | METHODS AND RELATED SYSTEMS FOR EXTRACTING ONE OR MORE CHEMICAL COMPOUNDS FROM CANNABIS PLANT MATERIAL | November 2021 | January 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17610422 | COMPOSITION COMPRISING EXTRACTS OF EUCOMMIA ULMOIDES, CROCUS SATIVUS AND/OR MAGNOLIA OFFICINALIS AND THE USE THEREOF IN THE TREATMENT OF SLEEP DISORDERS | November 2021 | April 2025 | Allow | 41 | 1 | 1 | No | No |
| 17520742 | Platelet filtration membrane and its applications thereof | November 2021 | January 2025 | Allow | 38 | 1 | 1 | No | No |
| 17595045 | MILK DERIVED EXTRACELLULAR VESICLES FOR USE IN TREATING INFLAMMATORY BOWEL DISEASE | November 2021 | May 2025 | Allow | 42 | 2 | 1 | Yes | No |
| 17608234 | COSMETIC CARE METHOD BASED ON PHOTOACTIVE EXTRACTS OF MICROALGAE | November 2021 | February 2025 | Allow | 39 | 1 | 1 | No | No |
| 17508053 | A THERAPEUTIC COMBINATION COMPRISING PORACTANT ALFA AND BUDESONIDE FOR THE TREATMENT OF EVOLVING BPD | October 2021 | April 2024 | Abandon | 30 | 2 | 0 | No | No |
| 17605096 | Nicotine Liquid Formulation | October 2021 | May 2025 | Allow | 43 | 2 | 1 | Yes | No |
| 17502784 | EXTRACTION METHOD | October 2021 | May 2023 | Allow | 19 | 0 | 0 | No | No |
| 17499261 | METHOD FOR IMPROVING SARCOPENIA BY USING PHELLINUS LINTEUS | October 2021 | January 2024 | Allow | 27 | 1 | 1 | No | No |
| 17498197 | FUCOIDAN HAIR GROWTH AGENT | October 2021 | September 2023 | Allow | 23 | 1 | 0 | No | No |
| 17496993 | Hygiene Base Composition, and Production Method and Application Method Thereof | October 2021 | April 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17495523 | VISCO-SUPPLEMENT COMPOSITIONS, AND METHODS OF USE THEREOF | October 2021 | August 2023 | Allow | 22 | 1 | 0 | No | No |
| 17494167 | ISOLATION METHOD FOR WATER INSOLUBLE LIGNIN COMPONENTS OF A BIOMASS | October 2021 | March 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17449701 | SKIN DULLNESS SUPPRESSING AGENT, AND SKIN BARRIER FUNCTION MAINTAINING OR IMPROVING AGENT | October 2021 | February 2024 | Allow | 28 | 2 | 0 | Yes | No |
| 17491564 | METHODS OF DIAGNOSING DISEASE | October 2021 | December 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17488449 | LIQUID INVISIBLE MASK WITH BROAD-SPECTRUM BACTERIOSTASIS AND PREPARATION METHOD AND USING METHOD THEREOF | September 2021 | May 2022 | Allow | 8 | 1 | 1 | No | No |
| 17599517 | CROTON LECHLERI COMPOSITIONS FOR USE IN THE TOPICAL TREATMENT OF ACUTE BACTERIAL SKIN OR SKIN STRUCTURE INFECTION | September 2021 | December 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17599495 | CROTON LECHLERI COMPOSITIONS FOR USE IN THE TREATMENT OF SKIN CANCER | September 2021 | December 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17448517 | EYE HEALTH SUPPLEMENT | September 2021 | March 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17448513 | EYE HEALTH SUPPLEMENT WITH CURCUMIN | September 2021 | March 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17480327 | METHOD FOR PRODUCING THERAPEUTIC AGENT FOR SKIN LESIONS, AND THERAPEUTIC AGENT FOR SKIN LESIONS | September 2021 | October 2023 | Allow | 25 | 2 | 0 | No | No |
| 17475513 | COMPOSITIONS AND METHOD FOR TREATING AND PREVENTING MALNUTRITION | September 2021 | July 2024 | Allow | 34 | 3 | 1 | Yes | No |
| 17474952 | TREATMENT OF TOBACCO ADDICTION BY A TOBACCO LEAF EXTRACT | September 2021 | September 2023 | Allow | 24 | 1 | 1 | No | No |
| 17438009 | ENZYMATICALLY TREATED CATECHIN PRODUCT WITH INCREASED CONTENTS OF GALLIC ACID, EPICATECHIN, AND EPIGALLOCATECHIN AND METHOD FOR PRODUCING SAME | September 2021 | November 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17467830 | Anti-Inflammatory Botanical Extract | September 2021 | January 2024 | Allow | 29 | 3 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner FIEBIG, RUSSELL G.
With a 10.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 31.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner FIEBIG, RUSSELL G works in Art Unit 1655 and has examined 943 patent applications in our dataset. With an allowance rate of 62.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner FIEBIG, RUSSELL G's allowance rate of 62.6% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by FIEBIG, RUSSELL G receive 1.87 office actions before reaching final disposition. This places the examiner in the 59% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by FIEBIG, RUSSELL G is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +23.9% benefit to allowance rate for applications examined by FIEBIG, RUSSELL G. This interview benefit is in the 74% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 27.9% of applications are subsequently allowed. This success rate is in the 40% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 38.4% of cases where such amendments are filed. This entry rate is in the 51% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 74.4% of appeals filed. This is in the 59% percentile among all examiners. Of these withdrawals, 55.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 48.9% are granted (fully or in part). This grant rate is in the 58% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.2% of allowed cases (in the 70% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.